News | Heart Valve Technology | January 16, 2017

Minneapolis Heart Institute Continues Early Feasibility Trial With Tendyne Device for Smaller Hearts

Tendyne Mitral valve

The Tendyne mitral valve being implanted. 

Tendyne Mitral valve anchoring system

An illustration showing the Tendyne mitral valve transapical anchoring system.

January 16, 2017 – In 2015, researchers and physicians at the Minneapolis Heart Institute Foundation (MHIF) were the first in the U.S. to conduct a transcatheter mitral valve replacement using a device from Abbott called the Tendyne Bioprosthetic Mitral Valve. This was part of a study to learn if such a device could help patients with damaged mitral valves who were not good candidates for conventional surgery. At that time, only one size of the device was available, and it was too large for patients with smaller hearts, including some women, because those smaller hearts did not have as much room for the valve. To address this issue, Tendyne developed a modified device, and MHIF recently used it to treat a female patient. MHIF was also the first in the U.S. to implant the new valve in a FDA-approved compassionate care case.

What differentiates the second-generation valve from the first version are subtle changes to the shape and dimensions of the valve's outer sealing frame, making it potentially more viable for patients with smaller hearts. These changes were intended to allow more patients to be treated than was previously possible. 
 
“We were turning away too many patients who weren't able to be treated with the original device,” said Dan Mans, the vice president of clinical and therapy development for Abbott's Tendyne business, the need for the smaller device became clear during the early trials for the first version. “The new version is intended to provide therapy for more patients. Once we developed it, we went back to patients who previously failed the screening and found many could be treated with the new device.”

 The principal investigators for the study being conducted at MHIF are Paul Sorajja, M.D., Saeid Farivar, M.D. and Wesley Pedersen, M.D.

“This new less-invasive technology could offer hope for improved quality of life to patients who have very limited options today," Pedersen said. "Transcatheter valve replacement treatment has proven very successful for aortic valve procedures, and we are hoping to see similar success for patients with poorly functioning mitral valves. Having an additional size of valve helps us track results with a larger patient population.” MHIF leads the U.S. in enrollments for the study, having done the most Tendyne implants in the world, with 16 implants completed.
 
Mitral regurgitation (MR) is a debilitating, progressive and life-threatening disease in which a leaky mitral valve causes a backward flow of blood in the heart. In the U.S., MR affects nearly one in 10 people age 75 and older. These patients often have difficulty with everyday activities, such as climbing stairs, and may require long periods of rest due to fatigue. Left untreated, the condition can raise the risk of irregular heartbeats, stroke, and heart failure, which can be deadly. Medications for the condition are limited to symptom management and do not stop the progression of the disease. Open heart mitral valve surgery is the standard treatment, but many people are not healthy enough to undergo this treatment.

For more information: www.mplsheart.org

 

Related Content

Abbott Tricuspid Valve Repair System Reduces Tricuspid Regurgitation at 30 Days
News | Heart Valve Technology | June 11, 2019
June 11, 2019 — Abbott recently announced positive late-breaking data from its TRILUMINATE...
DSM and SAT Partnering to Develop Next-Generation, Cost-Effective Heart Valve
News | Heart Valve Technology | June 04, 2019
Royal DSM recently announced a collaboration with Strait Access Technologies (SAT), to develop the world’s first...

The MitraClip is one example of a transcatheter mitral valve repair or replacement (TMVR) device used in the structural heart repair program at Henry Ford Hospital.

Podcast | Heart Valve Technology | May 31, 2019
Marvin Eng, M.D., structural fellowship director at Henry Ford Health System, and William O'Neill, M.D., director of
Illustration showing the catheter steps for the LAMPOON procedure designed to prevent left ventricular outflow tract (LVOT) obstruction . From Dr. Jaffar M. Khan and the Laboratory of Cardiovascular Intervention, led by Dr. Robert J. Lederman.

Figure 1: Illustration showing the catheter steps for the LAMPOON procedure. From Dr. Jaffar M. Khan and the Laboratory of Cardiovascular Intervention, led by Dr. Robert J. Lederman.

Feature | Heart Valve Technology | May 22, 2019
Researchers at the National, Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH
Edwards Announces Research Milestones for Pascal Transcatheter Mitral Valve Program
News | Heart Valve Technology | May 22, 2019
Edwards Lifesciences Corp. announced strategic clinical and regulatory milestones for its Edwards Pascal transcatheter...
Videos | Heart Valve Technology | May 20, 2019
A demonstration of how to calculate the neo-left ventricular outflow tract (neo-LVOT) on CT imaging for a transcathet
Study Finds TAVR Can Be Considered for Patients in All Surgical Risk Classes
News | Heart Valve Technology | May 08, 2019
Transcatheter aortic valve replacement (TAVR) has been studied as an alternative to surgical aortic valve replacement...
Boston Scientific Receives FDA Approval for Lotus Edge Aortic Valve System
Feature | Heart Valve Technology | April 23, 2019 | Dave Fornell, Editor
Boston Scientific Corp. announced it has received U.S. Food and Drug Administration (FDA) approval for the Lotus Edge...
New Consensus Document Explores Optimized Care for Valvular Heart Disease Patients
News | Heart Valve Technology | April 22, 2019
April 22, 2019 — Five cardiovascular professional societies released a new consensus document on optimizing care for
Mick Jagger Recovering After TAVR Procedure
News | Heart Valve Technology | April 08, 2019 | Jeff Zagoudis, Associate Editor
Rolling Stones frontman Mick Jagger is reportedly recovering after undergoing a transcatheter aortic valve valve...
Overlay Init